Skip to main content
. 2023 Jan 11;24(3):e56034. doi: 10.15252/embr.202256034

Figure 3. BTNL2 regulates colorectal tumorigenesis and colitis by regulating IL‐22 production.

Figure 3

  • A
    Mice were intraperitoneally injected with Fc or mIL‐22‐Fc recombinant proteins (5 μg/mouse) three times a week after the last round of DSS treatment. Arrows represent the AOM/DSS and Fc or mIL‐22‐Fc treatment.
  • B
    Purified Fc and mIL‐22‐Fc recombinant proteins were analyzed by SDS–PAGE and Coomassie brilliant blue staining.
  • C–E
    Representative colonic tumor burden (C), tumor number (D), and tumor size per mouse (E) which described in (A) were shown (n = 12).
  • F–H
    Body weight changes (F), colon length (G), and representative H&E images (H) of wild‐type control mice or BTNL2‐KO mice treated with Fc or mIL‐22‐Fc (ip. 5 μg/mouse) at day 0, 2, 4, and 6 during 2% DSS treatment were shown (n = 12).

Data information: All data are mean ± s.e.m. NS, not significant. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 based on one‐way ANOVA for (D, E, G) and two‐way ANOVA for (F). Each dot represents one mouse, n = 12 for (D–G). Data are representative of three biological replicates (B, C, left panel of G, H). Pooled data from three biological replicates are shown in (D–F) and in the right panel of (G).

Source data are available online for this figure.